Crossover Design on the Bioequivalence of Pharmaceuticals - A Case of Study

被引:0
|
作者
Teodoro, M. Filomena [1 ,2 ]
Andrade, Marina A. P. [3 ,4 ]
Oliveira, Teresa A. [5 ,6 ]
机构
[1] Naval Acad, Ctr Naval Res, CINAV, Portuguese Navy, P-2810001 Almada, Portugal
[2] Lisbon Univ, Ctr Computat & Stochast Math, Inst Super Tecn, CEMAT, P-1048001 Lisbon, Portugal
[3] Inst Univ Lisboa, ISCTE, P-1649026 Lisbon, Portugal
[4] Univ Lisbon, ISTAR, P-1649026 Lisbon, Portugal
[5] Univ Aberta, Dept Ciencias & Tecnol, P-1269001 Lisbon, Portugal
[6] Univ Lisbon, Fac Ciencias, CEAUL, P-1649014 Lisbon, Portugal
关键词
experimental design; clinical trials; analysis of variance; bio-equivalence; computational methods; CLINICAL-TRIALS; RANDOMIZATION; ALLOCATION;
D O I
10.1007/978-3-031-65223-3_15
中图分类号
TP18 [人工智能理论];
学科分类号
081104 ; 0812 ; 0835 ; 1405 ;
摘要
This study performs experimental design and analysis of variance in assessing the bioequivalence of two treatments, which involves evaluating the efficacy of different treatments administered to two distinct cohorts of patients: the control group and the test group. In order to compare the control group that received the reference medication, with the test/treatment group that received the investigational drug, a crossover experimental design was employed. The respective analysis of variance was conducted, taking into consideration both intra-subject and inter-subject variability in formulating the probabilistic model. This included specifying tests to detect carryover effects and period effects. The practical implementation of the proposed model involved validating the hypothesis, revealing that the carry-over effect was found to be not significant, when assessed at the usual levels of significance (1% and 5%). In terms of the treatments, it was concluded that there was statistical significance, leading to the assertion that the studied pharmaceuticals were not bioequivalent.
引用
收藏
页码:219 / 234
页数:16
相关论文
共 50 条
  • [41] A more powerful average bioequivalence analysis for the 22 crossover
    Stefanescu, Catalina
    Mehrotra, Devan V.
    [J]. COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2008, 37 (01) : 212 - 221
  • [42] Optimal adaptive sequential designs for crossover bioequivalence studies
    Xu, Jialin
    Audet, Charles
    DiLiberti, Charles E.
    Hauck, Walter W.
    Montague, Timothy H.
    Parr, Alan F.
    Potvin, Diane
    Schuirmann, Donald J.
    [J]. PHARMACEUTICAL STATISTICS, 2016, 15 (01) : 15 - 27
  • [43] Assurance (expected power) for planning crossover bioequivalence trials
    Ring, A.
    Lang, B.
    Kazaroho, C.
    Labes, D.
    Awounvo, J. S.
    Schuetz, H.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1622 - 1622
  • [44] Comparison of models for average bioequivalence in replicated crossover designs
    Willavize, Susan A.
    Morgenthien, Elizabeth A.
    [J]. PHARMACEUTICAL STATISTICS, 2006, 5 (03) : 201 - 211
  • [45] Considerations for crossover design in clinical study
    Lim, Chi-Yeon
    In, Junyong
    [J]. KOREAN JOURNAL OF ANESTHESIOLOGY, 2021, 74 (04) : 293 - 299
  • [46] Sample Size Determination and Study Design Impact on Dose-Scale Pharmacodynamic Bioequivalence: a Case Study Using Orlistat
    Xu, Lian
    Li, Sanwang
    Wu, Wei
    Cheng, Zeneng
    Xie, Feifan
    [J]. AAPS JOURNAL, 2024, 26 (04):
  • [47] Significance of Metabolites in Bioequivalence: Losartan Potassium as a Case Study
    Charoo, Naseem Ahmad
    Cristofoletti, Rodrigo
    Khatri, Aamer Roshanali
    Ali, Areeg Anwer
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (06) : 1584 - 1591
  • [48] Phenytoin clinical trial is case study for 'individual' bioequivalence
    Schumaker, RC
    Metzler, CM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI14 - PI14
  • [49] Pharmacokinetics and bioequivalence of Withania somnifera (Ashwagandha) extracts - A double blind, crossover study in healthy adults
    Kim, Se-Kwon
    Venkatesan, Jayachandran
    Rathi, Priyank
    Antony, Benny
    [J]. HELIYON, 2023, 9 (12)
  • [50] Pharmacokinetic Bioequivalence Crossover Study of Branded Generic and Innovator Formulations of the Cholesterol Lowering Agent Ezetimibe
    Palmer, Jonathan L.
    Kunhihitlu, Anil
    Costantini, Andrea
    Esquivel, Florencia
    Roush, John
    Edwards, Karina
    Hill, Thomas W. K.
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (03): : 242 - 248